Supreme Court Denies Stolt-Nielsen's Certiorari Petition Challenging the DOJ's Decision to Prosecution
Client Alert | less than 1 min read | 10.31.06
The Supreme Court denied Stolt-Nielsen's cert petition challenge the Department of Justice's Antitrust Divisions' decision to prosecution the corporation which had previously been granted immunity exchange for its cooperation in an antitrust investigation. Stolt-Nielsen had initially received leniency in exchange for providing information in the alleged customer allocation and bid-rigging in the liquid-cargo shipping market. The Antitrust Division later decided to lift the immunity when it decided Stolt-Nielsen had not lived up to the immunity agreement. After the Court's decision, Stolt-Nielsen announced that it will file a motion to dismiss the indictment based upon the amnesty agreement, on Nov. 22, in U.S. District Court in Philadelphia.
Insights
Client Alert | 4 min read | 04.09.26
DOJ Establishes National Fraud Enforcement Division
On April 7, 2026, Acting Attorney General Todd Blanche issued a memorandum establishing the National Fraud Enforcement Division (NFED) within the U.S. Department of Justice (DOJ). This new division will be dedicated to the centralized, coordinated investigation and prosecution of fraud against taxpayer dollars and taxpayer-funded programs. AAG Blanche acknowledged that, while DOJ has a “storied history of combatting fraud,” DOJ has “never adopted a comprehensive and coordinated approach to investigating and prosecuting fraud against taxpayer dollars and tax-payer funded programs.” The NFED was created to close that gap with its core mission being to “zealously investigate and prosecute those who steal or fraudulently misuse taxpayer dollars.”
Client Alert | 2 min read | 04.09.26
OMB Issues New Policy on Federal IT Transparency and Acquisition Oversight
Client Alert | 5 min read | 04.09.26
U.S. State Privacy Enforcement: Key Priorities and Practical Guidance From State Regulators
Client Alert | 4 min read | 04.08.26
Cosmetics Under the Microscope: FDA’s Expanding Regulatory Reach Under MoCRA
